Review





Similar Products

97
Welcony super rapid magnetic stimulator
Super Rapid Magnetic Stimulator, supplied by Welcony, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/super rapid magnetic stimulator/product/Welcony
Average 97 stars, based on 1 article reviews
super rapid magnetic stimulator - by Bioz Stars, 2026-06
97/100 stars
  Buy from Supplier

90
Nyxoah S.A genio implantable stimulator
Genio Implantable Stimulator, supplied by Nyxoah S.A, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/genio implantable stimulator/product/Nyxoah S.A
Average 90 stars, based on 1 article reviews
genio implantable stimulator - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

96
Digitimer North America LLC ds3
Ds3, supplied by Digitimer North America LLC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ds3/product/Digitimer North America LLC
Average 96 stars, based on 1 article reviews
ds3 - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier

96
Digitimer North America LLC isolated current stimulator
Isolated Current Stimulator, supplied by Digitimer North America LLC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/isolated current stimulator/product/Digitimer North America LLC
Average 96 stars, based on 1 article reviews
isolated current stimulator - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier

96
R&D Systems recombinant human macrophage colony
Recombinant Human Macrophage Colony, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human macrophage colony/product/R&D Systems
Average 96 stars, based on 1 article reviews
recombinant human macrophage colony - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier

86
Siemens Healthineers atellica im thyroid stimulating hormone 3 ultra tsh3 ul assay
Atellica Im Thyroid Stimulating Hormone 3 Ultra Tsh3 Ul Assay, supplied by Siemens Healthineers, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/atellica im thyroid stimulating hormone 3 ultra tsh3 ul assay/product/Siemens Healthineers
Average 86 stars, based on 1 article reviews
atellica im thyroid stimulating hormone 3 ultra tsh3 ul assay - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

90
Magstim Company r2 stimulator
R2 Stimulator, supplied by Magstim Company, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/r2 stimulator/product/Magstim Company
Average 90 stars, based on 1 article reviews
r2 stimulator - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

86
Soterix Medical direct current low intensity stimulator
Direct Current Low Intensity Stimulator, supplied by Soterix Medical, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/direct current low intensity stimulator/product/Soterix Medical
Average 86 stars, based on 1 article reviews
direct current low intensity stimulator - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Beijing Tiantan Biological subthalamic nucleus deep brain stimulation
Short-term (1 year) and long-term (3 years) dyskinesia outcomes, other motor outcomes, quality of life, neuropsychological outcomes, and cognitive functions of the included patients (n = 84) with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID) who underwent <t>subthalamic</t> nucleus deep brain <t>stimulation</t> (STN-DBS). ( A ) Dyskinesia outcomes such as UDysRS ( A-i ), time spent with LID (MDS-UPDRS-4.1), hours ( A-ii ), and functional impact of LID (MDS-UPDRS-4.2; A-iii ); ( B ) Other motor outcomes such as MDS-UPDRS-III (off-medicine; ( B-i )), MDS-UPDRS-III (on-medicine; ( B-ii )), MDS-UPDRS-II (daily living, ( B-iii )), MDS-UPDRS-IV (motor complications; ( B-iv) ), Hoehn & Yahr (off-medicine; ( B-v )), and LEDD, mg ( B-vi ); ( C ) Quality of life as PDQ-39; ( D ) Neuropsychological outcomes such as MDS-UPDRS-I (nonmotor experiences; ( D-i ), HAM-A ( D-ii ), and HAM-D ( D-iii ); and ( E ) Cognitive function as CMMS ( E-i ) and MoCA ( E-ii ). * P < 0.05 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction); ** P < 0.01 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction).
Subthalamic Nucleus Deep Brain Stimulation, supplied by Beijing Tiantan Biological, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/subthalamic nucleus deep brain stimulation/product/Beijing Tiantan Biological
Average 86 stars, based on 1 article reviews
subthalamic nucleus deep brain stimulation - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

Image Search Results


Short-term (1 year) and long-term (3 years) dyskinesia outcomes, other motor outcomes, quality of life, neuropsychological outcomes, and cognitive functions of the included patients (n = 84) with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID) who underwent subthalamic nucleus deep brain stimulation (STN-DBS). ( A ) Dyskinesia outcomes such as UDysRS ( A-i ), time spent with LID (MDS-UPDRS-4.1), hours ( A-ii ), and functional impact of LID (MDS-UPDRS-4.2; A-iii ); ( B ) Other motor outcomes such as MDS-UPDRS-III (off-medicine; ( B-i )), MDS-UPDRS-III (on-medicine; ( B-ii )), MDS-UPDRS-II (daily living, ( B-iii )), MDS-UPDRS-IV (motor complications; ( B-iv) ), Hoehn & Yahr (off-medicine; ( B-v )), and LEDD, mg ( B-vi ); ( C ) Quality of life as PDQ-39; ( D ) Neuropsychological outcomes such as MDS-UPDRS-I (nonmotor experiences; ( D-i ), HAM-A ( D-ii ), and HAM-D ( D-iii ); and ( E ) Cognitive function as CMMS ( E-i ) and MoCA ( E-ii ). * P < 0.05 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction); ** P < 0.01 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction).

Journal: Clinical Interventions in Aging

Article Title: Long-Term Surgical Outcomes and Influential Factors of Subthalamic Nucleus Deep Brain Stimulation for Dyskinesia in Parkinson’s Disease: A 3-Year Longitudinal Cohort Study

doi: 10.2147/CIA.S600031

Figure Lengend Snippet: Short-term (1 year) and long-term (3 years) dyskinesia outcomes, other motor outcomes, quality of life, neuropsychological outcomes, and cognitive functions of the included patients (n = 84) with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID) who underwent subthalamic nucleus deep brain stimulation (STN-DBS). ( A ) Dyskinesia outcomes such as UDysRS ( A-i ), time spent with LID (MDS-UPDRS-4.1), hours ( A-ii ), and functional impact of LID (MDS-UPDRS-4.2; A-iii ); ( B ) Other motor outcomes such as MDS-UPDRS-III (off-medicine; ( B-i )), MDS-UPDRS-III (on-medicine; ( B-ii )), MDS-UPDRS-II (daily living, ( B-iii )), MDS-UPDRS-IV (motor complications; ( B-iv) ), Hoehn & Yahr (off-medicine; ( B-v )), and LEDD, mg ( B-vi ); ( C ) Quality of life as PDQ-39; ( D ) Neuropsychological outcomes such as MDS-UPDRS-I (nonmotor experiences; ( D-i ), HAM-A ( D-ii ), and HAM-D ( D-iii ); and ( E ) Cognitive function as CMMS ( E-i ) and MoCA ( E-ii ). * P < 0.05 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction); ** P < 0.01 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction).

Article Snippet: The flowchart details the selection process for a study on Parkinson's patients with levodopa-induced dyskinesia who received subthalamic nucleus deep brain stimulation at Beijing Tiantan Hospital.

Techniques: Functional Assay

Relative changes (%) from baseline to short (1 year) term, baseline to long (3 years) term, and short (1 year) term to long (3 years) term dyskinesia outcomes; other motor outcomes; quality of life; neuropsychological outcomes; and cognitive functions of the included patients (n = 84) with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID) who underwent subthalamic nucleus deep brain stimulation (STN-DBS). ( A ) Dyskinesia outcomes such as UDysRS ( A-i ), time spent with LID (MDS-UPDRS-4.1), hours ( A-ii ), and functional impact of LID (MDS-UPDRS-4.2; ( A-iii) ); ( B ) Other motor outcomes such as MDS-UPDRS-III (off-medicine; ( B-i )), MDS-UPDRS-III (on-medicine; ( B-ii )), MDS-UPDRS-II (daily living, ( B-iii )), MDS-UPDRS-IV (motor complications; ( B-iv )), Hoehn & Yahr (off-medicine; ( B-v )), and LEDD, mg ( B-vi ); ( C ) Quality of life as PDQ-39; ( D ) Neuropsychological outcomes such as MDS-UPDRS-I (nonmotor experiences; ( D-i )), HAM-A ( D-ii ), and HAM-D ( D-iii ); and ( E ) Cognitive function as CMMS ( E-i ) and MoCA ( E-ii ). * P < 0.05 (one-way repeated-measures ANOVA or Friedman test, as appropriate, with post hoc pairwise comparisons adjusted by Bonferroni correction); ** P < 0.01 (one-way repeated-measures ANOVA or Friedman test, as appropriate, with post hoc pairwise comparisons adjusted by Bonferroni correction).

Journal: Clinical Interventions in Aging

Article Title: Long-Term Surgical Outcomes and Influential Factors of Subthalamic Nucleus Deep Brain Stimulation for Dyskinesia in Parkinson’s Disease: A 3-Year Longitudinal Cohort Study

doi: 10.2147/CIA.S600031

Figure Lengend Snippet: Relative changes (%) from baseline to short (1 year) term, baseline to long (3 years) term, and short (1 year) term to long (3 years) term dyskinesia outcomes; other motor outcomes; quality of life; neuropsychological outcomes; and cognitive functions of the included patients (n = 84) with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID) who underwent subthalamic nucleus deep brain stimulation (STN-DBS). ( A ) Dyskinesia outcomes such as UDysRS ( A-i ), time spent with LID (MDS-UPDRS-4.1), hours ( A-ii ), and functional impact of LID (MDS-UPDRS-4.2; ( A-iii) ); ( B ) Other motor outcomes such as MDS-UPDRS-III (off-medicine; ( B-i )), MDS-UPDRS-III (on-medicine; ( B-ii )), MDS-UPDRS-II (daily living, ( B-iii )), MDS-UPDRS-IV (motor complications; ( B-iv )), Hoehn & Yahr (off-medicine; ( B-v )), and LEDD, mg ( B-vi ); ( C ) Quality of life as PDQ-39; ( D ) Neuropsychological outcomes such as MDS-UPDRS-I (nonmotor experiences; ( D-i )), HAM-A ( D-ii ), and HAM-D ( D-iii ); and ( E ) Cognitive function as CMMS ( E-i ) and MoCA ( E-ii ). * P < 0.05 (one-way repeated-measures ANOVA or Friedman test, as appropriate, with post hoc pairwise comparisons adjusted by Bonferroni correction); ** P < 0.01 (one-way repeated-measures ANOVA or Friedman test, as appropriate, with post hoc pairwise comparisons adjusted by Bonferroni correction).

Article Snippet: The flowchart details the selection process for a study on Parkinson's patients with levodopa-induced dyskinesia who received subthalamic nucleus deep brain stimulation at Beijing Tiantan Hospital.

Techniques: Functional Assay